Cargando…

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camm, A John, Amarenco, Pierre, Haas, Sylvia, Hess, Susanne, Kirchhof, Paulus, van Eickels, Martin, Turpie, Alexander GG
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108256/ https://www.ncbi.nlm.nih.gov/pubmed/25083135 http://dx.doi.org/10.2147/VHRM.S63298

Ejemplares similares

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
por: Camm, A. John, et al.
Publicado: (2020)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
por: Turpie, Alexander GG, et al.
Publicado: (2012)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
por: Pisters, R., et al.
Publicado: (2017)

XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America
por: Martínez, Carlos Arturo Areán, et al.
Publicado: (2018)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
por: Haas, Sylvia, et al.
Publicado: (2014)

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis
por: Cano, Stefan, et al.
Publicado: (2018)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial
por: Hohnloser, Stefan H., et al.
Publicado: (2016)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis
por: Ageno, Walter, et al.
Publicado: (2014)

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
por: Bassand, Jean-Pierre, et al.
Publicado: (2018)

A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
por: Shim, Jaemin, et al.
Publicado: (2021)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines
por: Kirchhof, Paulus
Publicado: (2017)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program
por: De Caterina, Raffaele, et al.
Publicado: (2021)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients
por: Kwong, Louis, et al.
Publicado: (2015)

Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)
por: Ozaki, Yukio, et al.
Publicado: (2022)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Rivaroxaban in atrial fibrillation cardioversion: an update
por: Lavalle, Carlo, et al.
Publicado: (2019)

XANAP: A real‐world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia
por: Kim, Young‐Hoon, et al.
Publicado: (2018)

Catheter ablation in patients with persistent atrial fibrillation
por: Kirchhof, Paulus, et al.
Publicado: (2017)

Rationale and current perspective for early rhythm control therapy in atrial fibrillation
por: Van Gelder, Isabelle C., et al.
Publicado: (2011)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke
Publicado: (2010)

Initial rivaroxaban dosing in patients with atrial fibrillation
por: Ablefoni, Kaja, et al.
Publicado: (2019)

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial
por: Kotecha, Dipak, et al.
Publicado: (2017)

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice
por: Beyer-Westendorf, Jan, et al.
Publicado: (2017)

Almanac 2015: atrial fibrillation research in Heart
por: Jawad-Ul-Qamar, Muhammad, et al.
Publicado: (2016)

Recent advances in rhythm control for atrial fibrillation
por: Bond, Richard, et al.
Publicado: (2017)

An Introduction to Murine Models of Atrial Fibrillation
por: Riley, Genna, et al.
Publicado: (2012)

Atrial high-rate episodes and stroke prevention
por: Camm, A. John, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q2tv05ulm8cgnebahoq8rkadve